Satellite Biosciences announced receipt of a Rare Pediatric Disease (RPD) designation from the FDA for SB-101, an allogeneic off-the-shelf hepatocyte cell therapy, for the treatment of urea cycle disorders (UCDs) in infants with severe early-onset disease.
Upon approval of a qualifying marketing application, the RPD designation may make Satellite Bio eligible for a Priority Review Voucher (PRV), which the sponsor may use to obtain priority review for a future application or sell or transfer to another sponsor.
SB-101 is an allogeneic cell therapy consisting of expanded primary hepatocytes manufactured in advance, cryopreserved, and intended for infusion into patients. The mechanism does not target a single molecular receptor; rather, it seeks to restore urea cycle enzyme function by delivering functional hepatocytes that engraft at receptive sites and resume ammonia detoxification. Satellite Bio plans to initiate a Phase I/II clinical trial of SB-101 in 2026, though no trial registration has been identified in available records as of late April 2026, consistent with a pre-IND or early IND-enabling stage.
UCDs carry a mortality rate exceeding 25% in affected infants, with cognitive impairment documented in approximately half of surviving patients, according to the company. No curative treatment is currently available in the first weeks of life, and the standard of care remains supportive, centered on acute metabolic stabilization through nitrogen scavenger drugs, dietary protein restriction, and, in some cases, liver transplantation. A 2019 review in Human Molecular Genetics documented the field’s movement toward cell- and gene-based liver replacement strategies as investigators sought to address the limitations of conventional management, a trajectory into which SB-101 now enters at the clinical threshold.
Within the UCD therapeutic landscape, gene therapy has attracted the most development activity in recent years. Ultragenyx Pharmaceutical’s DTX301, an adeno-associated virus (AAV) serotype 8 vector encoding ornithine transcarbamylase (OTC), has been evaluated in adult OTC deficiency patients and represents one of the more advanced gene therapy programs in the urea cycle space, though its applicability to neonates remains constrained by AAV immunogenicity and liver dilution concerns in growing livers. Arctus Biotherapeutics and Selecta Biosciences have also advanced RNA- and immune-tolerance-based approaches targeting the same pathway. SB-101’s distinction lies in its modality: rather than delivering a corrective gene, it delivers functional cells intended to physically replace lost hepatocyte activity, an approach that does not depend on transduction efficiency or episomal gene persistence. Whether engraftment is durable enough to provide long-term metabolic correction in the neonatal liver environment is a question the planned Phase I/II trial will need to address.